AllPennyStocks.com CAPR Stock Sinks As Investors Brace For Imminent FDA Call On Deramiocel
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

CAPR Stock Sinks As Investors Brace For Imminent FDA Call On Deramiocel

The U.S. Food and Drug Administration’s target action date for Capricor’s biologics license application for Deramiocel is Saturday.

Other Penny Stock Movers

65,000 Patients a Year, Zero Approved Drugs, One Phase 3 Trial
$4.5 Million Could Unlock a Major Cannabis Market
Chilean Gold Developer Gains 15% on Final Permit Clearance
Most Popular
{{ index + 1 }}


Back to Top